ReviewBritish journal of cancer2004
Status of selenium in prostate cancer prevention.
Review in British journal of cancer, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 124 citations in OpenAlex.
- Selenium compounds for cancer prevention and therapy - human clinical trial considerations.Medical review (2021) · 2025Review
- Dietary antioxidants and flavonoids are inversely associated with prostate cancer risk and mortality: evidence from NHANES and machine learning.Frontiers in nutrition · 2025Article
- Selenium-More than Just a Fortuitous Sulfur Substitute in Redox Biology.Molecules (Basel, Switzerland) · 2023Review
- Review
- Antitumor Effects of Selenium.International journal of molecular sciences · 2021Review
- Selenium and Salt Interactions in Black Gram (Plants (Basel, Switzerland) · 2020Article
- Addition of Selenium Improves Immunomodulative Effects of Glucan.North American journal of medical sciences · 2016Article
- Imbalance in Protein Thiol Redox Regulation and Cancer-Preventive Efficacy of Selenium.Reactive oxygen species (Apex, N.C.) · 2016Article
- Trace elements in native and improved paddy rice from different climatic regions of Sri Lanka: implications for public health.SpringerPlus · 2016Article
- Methylseleninic acid sensitizes Notch3-activated OVCA429 ovarian cancer cells to carboplatin.PloS one · 2014Article
- Review
- The effects of selenium on tumor growth in epithelial ovarian carcinoma.Journal of gynecologic oncology · 2012Article
- Stable Isotope Resolved Metabolomics Analysis of Ribonucleotide and RNA Metabolism in Human Lung Cancer Cells.Metabolomics : Official journal of the Metabolomic Society · 2012Article
- Complementary and alternative medicines in prostate cancer: from bench to bedside?The oncologist · 2012Review
- Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities.Antioxidants & redox signaling · 2011Review
- Chemopreventive mechanisms of α-keto acid metabolites of naturally occurring organoselenium compounds.Amino acids · 2011Review
- Significant cancer prevention factor extraction: an association rule discovery approach.Journal of medical systems · 2011Article
- Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer.BJU international · 2011Article
- A whole-genome SNP association study of NCI60 cell line panel indicates a role of Ca2+ signaling in selenium resistance.PloS one · 2010Article
- Prevalence of micronutrient deficiency in popular diet plans.Journal of the International Society of Sports Nutrition · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The complete, 13 years, results of the Nutritional Prevention of Cancer Trial have been analysed, causing some speculation over the robustness of the previously reported findings of reduction of cancer risks by supplements of selenium (Se) to a cohort of older Americans. These analyses confirmed that Se supplementation was associated with marked reductions in risks to total (all-site except skin) carcinomas and to cancers of the prostate and colon-rectum. Of those deep-site treatment effects, the most robust was for prostate cancer, which was more frequent, and was confirmed by serum prostate-specific antigen level. Recent subgroup analyses showed Se supplementation reduced risk of cancer mostly among subjects who entered the trial with plasma Se levels in the bottom tertile of the cohort. Other recent findings have demonstrated that Se treatment can promote apoptosis in prostate cancer cells and, possibly, impair their proliferation through antiangiogenic effects. Thus, a body of basic understanding is developing by which one can understand and evaluate the results of the Nutritional Prevention of Cancer and future clinical trials. This understanding also requires inclusion of the mechanisms of Se transport and cellular uptake, so that appropriate inferences can be made from findings from cell culture systems, which tended to use effective Se doses much larger than relevant to cells in vivo. Also needed is information on the chemical speciation of Se in foods, so that Se delivery can be achieved in ways that are effective in reducing cancer risk and is also safe, accessible and sustainable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.